BRUSSELS & CHICAGO--(BUSINESS WIRE)--UCB today announced findings from a post-hoc analysis suggesting that disease activity response rates to Cimzia® (certolizumab pegol) plus methotrexate (MTX) as early as Week 12 helped predict the effect on structural joint damage in patients with moderate to severe rheumatoid arthritis (RA) at one year. Comparable responses were found by both RAPID3 (Routine Assessment of Patient Index Data 3) and EULAR (European League Against Rheumatism), suggesting that either response criteria could be used as predictors of structural joint damage in patients with moderate to severe RA. The analysis examined patients treated with certolizumab pegol plus MTX compared to placebo plus MTX. The data were presented at the American College of Rheumatology’s 2011 Annual Scientific Meeting in Chicago, IL (November 5-9, 2011).
